|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: VASN |
Gene summary for VASN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | VASN | Gene ID | 114990 |
| Gene name | vasorin | |
| Gene Alias | SLITL2 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0001666 | UniProtAcc | Q6EMK4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 114990 | VASN | P2T-E | Human | Esophagus | ESCC | 4.33e-62 | 1.19e+00 | 0.1177 |
| 114990 | VASN | P4T-E | Human | Esophagus | ESCC | 4.42e-02 | 1.97e-01 | 0.1323 |
| 114990 | VASN | P8T-E | Human | Esophagus | ESCC | 3.66e-12 | 4.33e-01 | 0.0889 |
| 114990 | VASN | P10T-E | Human | Esophagus | ESCC | 3.78e-04 | 1.53e-01 | 0.116 |
| 114990 | VASN | P11T-E | Human | Esophagus | ESCC | 2.34e-12 | 9.45e-01 | 0.1426 |
| 114990 | VASN | P12T-E | Human | Esophagus | ESCC | 4.44e-10 | 3.26e-01 | 0.1122 |
| 114990 | VASN | P15T-E | Human | Esophagus | ESCC | 4.77e-05 | 1.69e-01 | 0.1149 |
| 114990 | VASN | P16T-E | Human | Esophagus | ESCC | 3.55e-16 | 3.82e-01 | 0.1153 |
| 114990 | VASN | P21T-E | Human | Esophagus | ESCC | 3.64e-02 | 8.45e-02 | 0.1617 |
| 114990 | VASN | P22T-E | Human | Esophagus | ESCC | 4.68e-02 | 6.00e-02 | 0.1236 |
| 114990 | VASN | P26T-E | Human | Esophagus | ESCC | 2.36e-04 | 8.87e-02 | 0.1276 |
| 114990 | VASN | P27T-E | Human | Esophagus | ESCC | 2.57e-03 | 7.75e-02 | 0.1055 |
| 114990 | VASN | P31T-E | Human | Esophagus | ESCC | 4.76e-12 | 2.09e-01 | 0.1251 |
| 114990 | VASN | P39T-E | Human | Esophagus | ESCC | 4.11e-07 | 6.32e-02 | 0.0894 |
| 114990 | VASN | P42T-E | Human | Esophagus | ESCC | 3.41e-02 | 2.69e-01 | 0.1175 |
| 114990 | VASN | P44T-E | Human | Esophagus | ESCC | 3.00e-02 | 1.76e-01 | 0.1096 |
| 114990 | VASN | P47T-E | Human | Esophagus | ESCC | 1.31e-04 | 1.32e-01 | 0.1067 |
| 114990 | VASN | P48T-E | Human | Esophagus | ESCC | 7.66e-06 | 3.52e-02 | 0.0959 |
| 114990 | VASN | P52T-E | Human | Esophagus | ESCC | 1.27e-06 | 1.90e-01 | 0.1555 |
| 114990 | VASN | P54T-E | Human | Esophagus | ESCC | 3.36e-02 | 1.41e-01 | 0.0975 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00016667 | Liver | Cirrhotic | response to hypoxia | 108/4634 | 307/18723 | 2.51e-05 | 3.26e-04 | 108 |
| GO:00714536 | Liver | Cirrhotic | cellular response to oxygen levels | 67/4634 | 177/18723 | 7.10e-05 | 7.98e-04 | 67 |
| GO:000717911 | Liver | Cirrhotic | transforming growth factor beta receptor signaling pathway | 71/4634 | 198/18723 | 3.02e-04 | 2.65e-03 | 71 |
| GO:00714563 | Liver | Cirrhotic | cellular response to hypoxia | 56/4634 | 151/18723 | 4.86e-04 | 3.90e-03 | 56 |
| GO:00362946 | Liver | Cirrhotic | cellular response to decreased oxygen levels | 59/4634 | 161/18723 | 4.98e-04 | 3.98e-03 | 59 |
| GO:190384411 | Liver | Cirrhotic | regulation of cellular response to transforming growth factor beta stimulus | 47/4634 | 131/18723 | 2.87e-03 | 1.65e-02 | 47 |
| GO:000717811 | Liver | Cirrhotic | transmembrane receptor protein serine/threonine kinase signaling pathway | 111/4634 | 355/18723 | 2.98e-03 | 1.70e-02 | 111 |
| GO:00170152 | Liver | Cirrhotic | regulation of transforming growth factor beta receptor signaling pathway | 46/4634 | 128/18723 | 3.04e-03 | 1.72e-02 | 46 |
| GO:000166612 | Liver | HCC | response to hypoxia | 172/7958 | 307/18723 | 1.06e-06 | 1.59e-05 | 172 |
| GO:003629312 | Liver | HCC | response to decreased oxygen levels | 179/7958 | 322/18723 | 1.29e-06 | 1.87e-05 | 179 |
| GO:007048212 | Liver | HCC | response to oxygen levels | 191/7958 | 347/18723 | 1.42e-06 | 2.03e-05 | 191 |
| GO:007155921 | Liver | HCC | response to transforming growth factor beta | 141/7958 | 256/18723 | 3.08e-05 | 3.16e-04 | 141 |
| GO:007156021 | Liver | HCC | cellular response to transforming growth factor beta stimulus | 137/7958 | 250/18723 | 5.47e-05 | 5.14e-04 | 137 |
| GO:007145311 | Liver | HCC | cellular response to oxygen levels | 98/7958 | 177/18723 | 3.63e-04 | 2.52e-03 | 98 |
| GO:003629411 | Liver | HCC | cellular response to decreased oxygen levels | 90/7958 | 161/18723 | 4.03e-04 | 2.72e-03 | 90 |
| GO:007145611 | Liver | HCC | cellular response to hypoxia | 84/7958 | 151/18723 | 7.57e-04 | 4.56e-03 | 84 |
| GO:000717921 | Liver | HCC | transforming growth factor beta receptor signaling pathway | 106/7958 | 198/18723 | 1.09e-03 | 6.23e-03 | 106 |
| GO:19038442 | Liver | HCC | regulation of cellular response to transforming growth factor beta stimulus | 72/7958 | 131/18723 | 2.65e-03 | 1.27e-02 | 72 |
| GO:001701511 | Liver | HCC | regulation of transforming growth factor beta receptor signaling pathway | 70/7958 | 128/18723 | 3.56e-03 | 1.59e-02 | 70 |
| GO:0051775 | Liver | HCC | response to redox state | 12/7958 | 15/18723 | 3.56e-03 | 1.59e-02 | 12 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| VASN | SNV | Missense_Mutation | novel | c.350N>G | p.Asn117Ser | p.N117S | Q6EMK4 | protein_coding | tolerated(0.08) | possibly_damaging(0.621) | TCGA-GM-A3NY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| VASN | SNV | Missense_Mutation | novel | c.1816G>A | p.Ala606Thr | p.A606T | Q6EMK4 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| VASN | SNV | Missense_Mutation | novel | c.1817N>T | p.Ala606Val | p.A606V | Q6EMK4 | protein_coding | deleterious(0.04) | benign(0.115) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| VASN | SNV | Missense_Mutation | rs755829190 | c.952N>A | p.Val318Ile | p.V318I | Q6EMK4 | protein_coding | tolerated(0.31) | benign(0.007) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| VASN | SNV | Missense_Mutation | c.80G>A | p.Gly27Asp | p.G27D | Q6EMK4 | protein_coding | tolerated(0.43) | benign(0.076) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| VASN | SNV | Missense_Mutation | c.1591T>A | p.Tyr531Asn | p.Y531N | Q6EMK4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| VASN | SNV | Missense_Mutation | rs199795973 | c.409C>T | p.Arg137Cys | p.R137C | Q6EMK4 | protein_coding | deleterious(0.04) | benign(0.013) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| VASN | SNV | Missense_Mutation | rs113954688 | c.647N>A | p.Arg216His | p.R216H | Q6EMK4 | protein_coding | tolerated(0.19) | benign(0.005) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| VASN | SNV | Missense_Mutation | c.1187N>A | p.Ala396Asp | p.A396D | Q6EMK4 | protein_coding | tolerated(0.17) | benign(0.235) | TCGA-DC-4749-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| VASN | insertion | Frame_Shift_Ins | novel | c.340_341insA | p.Ile115AsnfsTer4 | p.I115Nfs*4 | Q6EMK4 | protein_coding | TCGA-AZ-6606-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folfiri | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |